^
Association details:
| Biomarker: | PIK3CA mutation + ESR1 wild-type |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | MEN1611 (PI3K inhibitor) + Orserdu (elacestrant) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2849 / 7 - The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models
Published date:
03/15/2023
Excerpt:
Here we have evaluated the antitumor activity of Elacestrant, the oral selective estrogen receptor degrader (SERD) and antagonist, in combination with the σ-sparing PI3K inhibitor MEN1611, in vitro and in vivo in different clinically relevant BC Patient-Derived Xenograft (PDX) models....In the PDX models HBxC-19 and CTG-2308, wild-type for ESR1 gene, but harboring a PIK3CA mutation, the TVI of the combination was 94.6% and 61.4%, respectively. In the latter model the combination was significantly superior to the single agents.
